The short answer
SURPASS-4 randomised 2,002 participants with type 2 diabetes and increased cardiovascular risk to tirzepatide or insulin glargine over 52 weeks. Del Prato and colleagues published it in the Lancet in November 2021, and its sulfonylurea subgroup isolates the glucose-dependence effect.
Key facts
- Published
- Lancet, 13 November 2021 (PMID 34672967)
- Randomised
- 2,002
- Dosed
- 1,995 (glargine n=1,000)
- Design
- Randomised, open-label, parallel-group
- HbA1c at 52 weeks
- −2.43% (10 mg), −2.58% (15 mg) vs −1.44%
- Hypoglycaemia overall
- 6-9% vs 19%
- Without sulfonylurea
- 1-3% vs 16%
- MACE-4
- HR 0.74 (95% CI 0.51-1.08)
Why comparing against insulin is the informative design
Insulin lowers glucose regardless of what glucose is doing; it is the archetype of a glucose-independent agent. Setting an incretin against it puts the two mechanisms side by side in one population, which is where a difference in hypoglycaemia should appear if glucose-dependence means anything.
The headline glycaemic result
At 52 weeks, mean HbA1c fell 2.43% on tirzepatide 10 mg and 2.58% on 15 mg, against 1.44% with glargine. So the incretin lowered glucose substantially more than insulin titrated in a trial setting, which makes the hypoglycaemia comparison more striking rather than less.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The subgroup that carries the mechanism
Hypoglycaemia, defined as glucose below 54 mg/dL or clinically severe, occurred in 6 to 9% on tirzepatide against 19% on glargine. Among participants not taking a sulfonylurea the figures were 1 to 3% against 16%. That split isolates the effect: remove the glucose-independent oral agent and the incretin's rate falls to near-negligible while insulin's barely moves.
What the sulfonylurea contribution demonstrates
That the residual hypoglycaemia seen with the incretin was largely attributable to something else in the regimen. A compound showing 1 to 3% alone and 6 to 9% in combination has not become more dangerous; the combination has. This is as clear a natural demonstration of glucose-dependence as trial data offers.
The cardiovascular finding
Adjudicated MACE-4 events (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 participants, with a hazard ratio of 0.74 and a confidence interval from 0.51 to 1.08. The interval crosses one, so this establishes no excess risk rather than demonstrating benefit. Sixty deaths occurred, 25 on tirzepatide and 35 on glargine.
The design limitation
Open-label. Blinding an injectable titrated against glucose readings is impractical, and participants and investigators knew their assignment. That is a real limitation for subjectively reported outcomes, though less consequential for a laboratory-defined endpoint like glucose below a threshold.
What this does not concern
Research material. Both compounds are licensed medicines administered in a registered trial under clinical supervision, in people with type 2 diabetes and elevated cardiovascular risk. Nothing supplied on this site affects blood glucose or is an alternative to any diabetes treatment.
Quick reference
| Tirzepatide | Glargine | |
|---|---|---|
| HbA1c change, 15 mg | −2.58% | −1.44% |
| Hypoglycaemia, overall | 6-9% | 19% |
| Hypoglycaemia, no sulfonylurea | 1-3% | 16% |
| Deaths | 25 (3%) | 35 (4%) |
Frequently asked questions
What did SURPASS-4 compare?
Tirzepatide against insulin glargine in 2,002 randomised participants with type 2 diabetes and increased cardiovascular risk, over 52 weeks.
Why is the sulfonylurea subgroup important?
Without a sulfonylurea, tirzepatide hypoglycaemia was 1-3% against glargine's 16%, isolating the glucose-independent agent as the source of most of the residual risk.
Did it show cardiovascular benefit?
No. The MACE-4 hazard ratio was 0.74 with an interval from 0.51 to 1.08, which crosses one, establishing no excess risk rather than benefit.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDel Prato S et al., Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre trial. Lancet 2021 (PMID 34672967)pubmed.ncbi.nlm.nih.gov
- PubMedLiu QK, Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol 2024 (PMID 39114288)pubmed.ncbi.nlm.nih.gov
- PubMedFilippatos TD et al., Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 2014 (PMID 26177483)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- TRIUMPH-4: The First Retatrutide Phase 3 to Read OutTRIUMPH-4 randomised 445 adults with obesity and knee osteoarthritis. Co-primary endpoints, two estimands, and a pain result that did not track the dose.
- VESPER: What Is Actually Registered for BerobenatideSix VESPER trials, from a 239-person Phase 2b to a 3,578-person Phase 3. Registry records, enrolment, completion dates, and which acronyms are registered.
- SOLIS-1: Testing Two Compounds and Their Combination at OnceSOLIS-1 is a Phase 2b umbrella study of an estimated 872 participants, testing an amylin analogue, an ultra-long-acting GLP-1 agonist, and both in combination.
- Reading Deal Structure as a Statement About EvidencePfizer paid $65.60 a share for Metsera plus a CVR of up to $20.65 tied to three milestones. That structure encodes how uncertain the buyer thought the data was.
- The Gap Is Smaller Outside the Trial, and It Widens With TimeA 2,396-patient US cohort found a 2.32-point weight difference at six months. The head-to-head trial found 6.5 points at 72 weeks. Both figures are right.